Clinical Trials Directory

Trials / Completed

CompletedNCT04239950

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
316 (actual)
Sponsor
Mochida Pharmaceutical Company, Ltd. · Industry
Sex
All
Age
18 Years – 74 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in Chinese patients with severe hypertriglyceridemia.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboPlacebo
DRUGEthyl IcosapentateEthyl Icosapentate

Timeline

Start date
2020-05-09
Primary completion
2023-07-20
Completion
2023-07-20
First posted
2020-01-27
Last updated
2024-07-15

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04239950. Inclusion in this directory is not an endorsement.